Detailed explanation of the role and efficacy of ixazomib

Data from the primary study showed that ixazomib improved progression-free survival in patients. However, due to uncertainty about the degree of improvement after a later analysis, further confirmation of its efficacy data is needed. By adding lenalidomide and dexamethasone, ixazomib does not appear to significantly increase the frequency of serious side effects, and patients can take capsules at home.

Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds to and inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells derived from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide shows synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib showed antitumor activity in a mouse xenograft model of multiple myeloma.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.